Wikia

Psychology Wiki

Changes: Prodrug

Edit

Back to page

 
 
Line 1: Line 1:
 
{{BioPsy}}
 
{{BioPsy}}
A '''prodrug''' is a [[Pharmacology|pharmacological]] substance ([[medication|drug]]) which is administered in an inactive (or significantly less active) form. Once administered, the prodrug is [[metabolism|metabolised]] in the body [[in vivo]] into the active compound.
+
A '''prodrug''' is a [[Pharmacology|pharmacological]] substance ([[medication|drug]]) that is administered in an inactive (or significantly less active) form. Once administered, the prodrug is [[drug metabolism|metabolised]] [[in vivo]] into an '''active metabolite'''. The rationale behind the use of a prodrug is generally for absorption, distribution, metabolism, and excretion ([[ADME]]) optimization. Prodrugs are usually designed to improve oral [[bioavailability]], with poor absorption from the [[gastrointestinal tract]] usually being the limiting factor.
   
==Rationale==
+
Additionally, the use of a prodrug strategy increases the selectivity of the drug for its intended target. An example of this can be seen in many [[chemotherapy]] treatments, in which the reduction of adverse effects is always of paramount importance. Drugs used to target [[Hypoxia (medical)|hypoxic]] [[cancer cells]], through the use of [[redox]]-activation, utilise the large quantities of [[reductase]] [[enzyme]] present in the hypoxic cell to convert the drug into its [[cytotoxic]] form, essentially activating it. As the prodrug has low cytotoxicity prior to this activation, there is a markedly lower chance of it "attacking" healthy, non-cancerous cells which reduces the side-effects associated with these [[chemotherapeutic]] agents.
The rationale behind the use of a prodrug is generally for [[ADME]] optimization. Prodrugs are usually designed to improve oral [[bioavailability]] - poor absorption from the [[gastrointestinal tract]] is usually the limiting factor, and is often due to the [[chemical]] properties of the drug.
 
   
Equally, the use of a prodrug strategy increases the selectivity of the drug for its intended target. An example of this can be seen in many [[anti-cancer]] treatments, in which the reduction of adverse effects is always of paramount importance. Drugs used to target [[Hypoxia (medical)|hypoxic]] [[cancer cells]], through the use of [[redox]]-activation, utilise the large quantities of [[reductase]] [[enzyme]] present in the hypoxic cell to convert the drug into its cytotoxic form, essentially activating it. As the prodrug has low cytotoxicity prior to this activation, there is a markedly lower chance of it "attacking" healthy, non-cancerous cells which reduces the side-effects associated with these [[chemotherapeutic]] agents
+
In [[rational drug design]], the knowledge of chemical properties likely to improve absorption and the major metabolic pathways in the body allows the modification of the structure of new chemical entities for improved bioavailability. Sometimes the use of a prodrug is unintentional, however, especially in the case of [[Serendipity|serendipitous]] drug discoveries, and the drug is only identified as a prodrug after extensive drug metabolism studies.
   
In [[rational drug design]], the knowledge of chemical properties likely to improve absorption and the major metabolic pathways in the body allows the modification of the structure of new chemical entities for improved bioavailability. However, sometimes the use of a prodrug is unintentional, especially in the case of [[Serendipity|serendipitous]] drug discoveries, and the drug is only identified as a prodrug after extensive drug metabolism studies.
+
== Classification ==
  +
Prodrugs can be classified into two major types, based on their cellular sites of conversion into the final active drug form, with Type I being those that are converted intracellularly (e.g., anti-viral nucleoside analogs, lipid-lowering statins,), and Type II being those that are converted extracellularly, especially in digestive fluids or the systemic circulation (e.g., etoposide phosphate, valganciclovir, fosamprenavir, antibody-, gene- or virus-directed enzyme prodrugs [ADEP/GDEP/VDEP] for chemotherapy or immunotherapy). Both types can be further categorized into Subtypes, i.e. Type IA, IB and Type IIA, IIB, and IIC based on whether or not the intracellular converting location is also the site of therapeutic action, or the conversion occurs in the gastrointestinal (GI) fluids or systemic circulation (see Table 1).
   
Prodrugs also occur naturally.
+
Type IA prodrugs include many antimicrobial and chemotherapy agents (e.g., 5-flurouracil). Type IB agents rely on metabolic enzymes, especially in hepatic cells, to convert the prodrugs intracellularly to active drugs. Type II prodrugs are converted extracelluarly, either in the milieu of GI fluids (Type IIA), within the systemic circulation and/or other extracellular fluid compartments (Type IIB), or near therapeutic target tissues/cells (Type IIC), relying on common enzymes such as esterases and phosphatases or target directed enzymes. Importantly, prodrugs can belong to multiple subtypes (i.e., Mixed-Type). A Mixed-Type prodrug is one that is converted at multiple sites, either in parallel or sequential steps. For example, a prodrug, which is converted concurrently in both target cells and metabolic tissues, could be designated as a “Type IA/IB” prodrug (e.g., HMG Co-A reductase inhibitors and some chemotherapy agents; note the symbol “ / ” applied here). When a prodrug is converted sequentially, for example initially in GI fluids then systemically within the target cells, it is designated as a “Type IIA-IA” prodrug (e.g., tenofovir disoproxil fumarate; note the symbol “ - ” applied here). Many ADEPs, VDEPs, GDEPs and futuristic nanoparticle- or nanocarrier-linked drug moieties can understandably be Sequential Mixed-Type prodrugs. To differentiate these two Subtypes, the symbol dash “ - ” is used to designate and to indicate sequential steps of conversion, and is meant to distinguish from the symbol slash “ / ” used for the Parallel Mixed-Type prodrugs
  +
<ref>see Table 1; Wu,K.M.: A New Classification of Prodrugs: Regulatory Perspectives Pharmaceuticals 2:77-81, 2009.(http://dx.doi.org/10.3390/ph2030077).</ref>,<ref>see Table 1; Wu, K.M.; Farrelly, J.: Regulatory Perspectives of Type II Prodrug Development and Time-Dependent Toxicity Management: Nonclinical Pharm/Tox Analysis and the Role of Comparative Toxicology. Toxicology 2007, 236, 1–6. (http://dx.doi.org/10.1016/j.tox.2007.04.005)</ref>.
   
==Selected examples==
+
{| class="wikitable"
*[[Enalapril]] is converted by [[esterase]] to the active [[enalaprilat]].
+
|+ Table 1: Classification of prodrugs
*[[Valaciclovir]] is converted by esterase to the active [[aciclovir]].
+
|-
*[[Levodopa]] is converted by DOPA decarboxylase to the active [[dopamine]].
+
! Type !! Converting site !! Subtype !! Tissue location of conversion !! Examples
*[[Psilocybin]] is dephosphorylated to the active [[psilocin]].
+
|-
*[[Heroin]] is deacetylated by esterase to the active [[morphine]].
+
| Type I || Intracellular || Type IA || Therapeutic target tissues/cells || [[Acyclovir]], [[5-Flurouracil]], [[Cyclophosphamide]], [[Diethlstilbestrol diphosphate]],
  +
[[L-Dopa]], [[6-Mercaptopurine]], [[Mitomycine C]], [[Zidovudine]]
  +
|-
  +
| Type I || Intracellular || Type IB || Metabolic tissues (liver, GI mucosal cell,lung etc) || [[Cabamazepine]], [[Captopril]], [[Carisoprodol]], [[Heroin]], [[Molsidomine]], [[Paliperidone]],
  +
[[Phenacetin]], [[Primidone]], [[Psilocybin]], [[Suldinac]], [[Tetrahydrofurfuryl disulfide]]
  +
|-
  +
| Type II || Extracellular || Type IIA || GI fluids || [[Lisdexamfetamine]], [[Loperamide oxide]], [[Oxyphenisatin]], [[Sulfasalazine]]
  +
|-
  +
| Type II || Extracellular || Type IIB || Systemic circulation and Other Extracellular Fluid Compartments || [[Acetylsalicylate]], [[Bacampicillin]], [[Bambuterol]], [[Chloramphenicol succinate]],
  +
[[Dihydropyridine pralixoxime]], [[Dipivefrin]], [[Fosphenytoin]]
  +
|-
  +
| Type II || Extracellular || Type IIC || Therapeutic Target Tissues/Cells || [[ADEPs]], [[GDEPs]], [[VDEPs]]
  +
|}''Adapted from Pharmaceuticals (2:77-81, 2009) and Toxicology (236:1-6, 2007).''
  +
  +
== Examples ==
  +
* [[Carisoprodol]] is metabolized into [[meprobamate]]. Carisoprodol is not a controlled substance in the United States, but meprobamate is classified as a potentially addictive [[controlled substance]] that can produce dangerous and painful withdrawal symptoms upon discontinuation of the drug.
  +
* [[Enalapril]] is converted by [[esterase]] to the active [[enalaprilat]].
  +
* [[Valacyclovir]] is converted by esterase to the active [[acyclovir]].
  +
* [[Fosamprenavir]] is hydrolysed to the active [[amprenavir]].
  +
* [[Levodopa]] is converted by DOPA decarboxylase to the active [[dopamine]].
  +
* [[Chloramphenicol]] succinate ester is used as an [[intravenous]] prodrug of chloramphenicol, because pure chloramphenicol does not dissolve in water.
  +
* [[Psilocybin]] is dephosphorylated to the active [[psilocin]].
  +
* [[Heroin]] is deacetylated by esterase to the active [[morphine]].
  +
* [[Codeine]] is demethylated by the liver enzyme [[CYP2D6]] to the active [[morphine]], as well as several other compounds that may be active in analgesia.
  +
* [[Molsidomine]] is metabolized into [[SIN-1]] which decomposes into the active compound [[nitric oxide]].
  +
* [[Paliperidone]] (Invega) is an atypical antipsychotic for schizophrenia. It is the active metabolite of [[risperidone]] (Risperdal).
  +
* [[Prednisone]], a synthetic [[corticosteroid|cortico-steroid]] drug, is converted by the liver into the active drug [[prednisolone]], which is also a steroid.
  +
* [[Primidone]] is metabolized by [[cytochrome P450]] enzymes into [[phenobarbital]], which is major, and [[phenylethylmalonamide]], which is minor.
  +
* [[Dipivefrine]], given topically as an anti-[[glaucoma]] drug, is converted to [[epinephrine]].
  +
* [[Lisdexamfetamine]] is metabolized in the small intestine to produce [[dextroamphetamine]] at a controlled (slow) rate for the treatment of [[attention-deficit hyperactivity disorder]]
  +
* [[Diethylpropion]] is a diet pill that does not become active as a monoamine releaser or reuptake inhibitor until it has been ''N''-dealkylated to [[ethylpropion]].
  +
  +
== See also ==
  +
* [[Toxification]]
  +
  +
==References==
  +
{{reflist}}
  +
  +
== External links ==
  +
* [http://www.mdpi.com/journal/molecules/special_issues/prodrugs Special Issue on Prodrugs: from Design to Applications]
   
 
[[Category:Pharmacology]]
 
[[Category:Pharmacology]]
  +
[[Category:Prodrugs|*]]
   
  +
<!--
 
[[ca:Profàrmac]]
 
[[ca:Profàrmac]]
 
[[de:Prodrug]]
 
[[de:Prodrug]]
  +
[[es:Profármaco]]
  +
[[eu:Profarmako]]
  +
[[fr:Prodrogue]]
 
[[it:Profarmaco]]
 
[[it:Profarmaco]]
  +
[[ja:プロドラッグ]]
  +
[[pl:Prolek]]
  +
[[pt:Pró-fármaco]]
  +
[[ru:Пролекарства]]
 
[[sl:Predzdravilo]]
 
[[sl:Predzdravilo]]
 
[[fi:Aihiolääke]]
 
[[fi:Aihiolääke]]
  +
[[sv:Prodrog]]
 
[[th:โปรดรัก]]
 
[[th:โปรดรัก]]
 
[[zh:前体药物]]
 
[[zh:前体药物]]
  +
-->
 
{{enWP|Prodrug}}
 
{{enWP|Prodrug}}

Latest revision as of 07:50, March 3, 2010

Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)


A prodrug is a pharmacological substance (drug) that is administered in an inactive (or significantly less active) form. Once administered, the prodrug is metabolised in vivo into an active metabolite. The rationale behind the use of a prodrug is generally for absorption, distribution, metabolism, and excretion (ADME) optimization. Prodrugs are usually designed to improve oral bioavailability, with poor absorption from the gastrointestinal tract usually being the limiting factor.

Additionally, the use of a prodrug strategy increases the selectivity of the drug for its intended target. An example of this can be seen in many chemotherapy treatments, in which the reduction of adverse effects is always of paramount importance. Drugs used to target hypoxic cancer cells, through the use of redox-activation, utilise the large quantities of reductase enzyme present in the hypoxic cell to convert the drug into its cytotoxic form, essentially activating it. As the prodrug has low cytotoxicity prior to this activation, there is a markedly lower chance of it "attacking" healthy, non-cancerous cells which reduces the side-effects associated with these chemotherapeutic agents.

In rational drug design, the knowledge of chemical properties likely to improve absorption and the major metabolic pathways in the body allows the modification of the structure of new chemical entities for improved bioavailability. Sometimes the use of a prodrug is unintentional, however, especially in the case of serendipitous drug discoveries, and the drug is only identified as a prodrug after extensive drug metabolism studies.

Classification Edit

Prodrugs can be classified into two major types, based on their cellular sites of conversion into the final active drug form, with Type I being those that are converted intracellularly (e.g., anti-viral nucleoside analogs, lipid-lowering statins,), and Type II being those that are converted extracellularly, especially in digestive fluids or the systemic circulation (e.g., etoposide phosphate, valganciclovir, fosamprenavir, antibody-, gene- or virus-directed enzyme prodrugs [ADEP/GDEP/VDEP] for chemotherapy or immunotherapy). Both types can be further categorized into Subtypes, i.e. Type IA, IB and Type IIA, IIB, and IIC based on whether or not the intracellular converting location is also the site of therapeutic action, or the conversion occurs in the gastrointestinal (GI) fluids or systemic circulation (see Table 1).

Type IA prodrugs include many antimicrobial and chemotherapy agents (e.g., 5-flurouracil). Type IB agents rely on metabolic enzymes, especially in hepatic cells, to convert the prodrugs intracellularly to active drugs. Type II prodrugs are converted extracelluarly, either in the milieu of GI fluids (Type IIA), within the systemic circulation and/or other extracellular fluid compartments (Type IIB), or near therapeutic target tissues/cells (Type IIC), relying on common enzymes such as esterases and phosphatases or target directed enzymes. Importantly, prodrugs can belong to multiple subtypes (i.e., Mixed-Type). A Mixed-Type prodrug is one that is converted at multiple sites, either in parallel or sequential steps. For example, a prodrug, which is converted concurrently in both target cells and metabolic tissues, could be designated as a “Type IA/IB” prodrug (e.g., HMG Co-A reductase inhibitors and some chemotherapy agents; note the symbol “ / ” applied here). When a prodrug is converted sequentially, for example initially in GI fluids then systemically within the target cells, it is designated as a “Type IIA-IA” prodrug (e.g., tenofovir disoproxil fumarate; note the symbol “ - ” applied here). Many ADEPs, VDEPs, GDEPs and futuristic nanoparticle- or nanocarrier-linked drug moieties can understandably be Sequential Mixed-Type prodrugs. To differentiate these two Subtypes, the symbol dash “ - ” is used to designate and to indicate sequential steps of conversion, and is meant to distinguish from the symbol slash “ / ” used for the Parallel Mixed-Type prodrugs [1],[2].

Table 1: Classification of prodrugs
Type Converting site Subtype Tissue location of conversion Examples
Type I Intracellular Type IA Therapeutic target tissues/cells Acyclovir, 5-Flurouracil, Cyclophosphamide, Diethlstilbestrol diphosphate,

L-Dopa, 6-Mercaptopurine, Mitomycine C, Zidovudine

Type I Intracellular Type IB Metabolic tissues (liver, GI mucosal cell,lung etc) Cabamazepine, Captopril, Carisoprodol, Heroin, Molsidomine, Paliperidone,

Phenacetin, Primidone, Psilocybin, Suldinac, Tetrahydrofurfuryl disulfide

Type II Extracellular Type IIA GI fluids Lisdexamfetamine, Loperamide oxide, Oxyphenisatin, Sulfasalazine
Type II Extracellular Type IIB Systemic circulation and Other Extracellular Fluid Compartments Acetylsalicylate, Bacampicillin, Bambuterol, Chloramphenicol succinate,

Dihydropyridine pralixoxime, Dipivefrin, Fosphenytoin

Type II Extracellular Type IIC Therapeutic Target Tissues/Cells ADEPs, GDEPs, VDEPs
Adapted from Pharmaceuticals (2:77-81, 2009) and Toxicology (236:1-6, 2007).

Examples Edit

See also Edit

ReferencesEdit

  1. see Table 1; Wu,K.M.: A New Classification of Prodrugs: Regulatory Perspectives Pharmaceuticals 2:77-81, 2009.(http://dx.doi.org/10.3390/ph2030077).
  2. see Table 1; Wu, K.M.; Farrelly, J.: Regulatory Perspectives of Type II Prodrug Development and Time-Dependent Toxicity Management: Nonclinical Pharm/Tox Analysis and the Role of Comparative Toxicology. Toxicology 2007, 236, 1–6. (http://dx.doi.org/10.1016/j.tox.2007.04.005)

External links Edit

This page uses Creative Commons Licensed content from Wikipedia (view authors).

Around Wikia's network

Random Wiki